Effect of Preconditioning with Rosuvastatin on Myocardial Reperfusion Left Ventricular Remodeling and Myocardial Injury after PCI for Acute Myocardial Infarction
LI Yinjun, XING Yu, XING Yunyun, et al
Shenyang Fourth People’s Hospital, Liaoning Shenyang 110031, China
Abstract：Objective: To investigate the effect of different preconditioning with rosuvastatin on myocardial reperfusion, left ventricular remodeling and serum creatine kinase isoenzyme (CK-MB) and troponin T (cTnT) levels after percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Methods: 150 patients with AMI were randomly divided into the observation group and the control group. The observation group was treated with oral rosuvastatin of 20 mg/d before operation and at 14 days after operation, and the dose was adjusted to 10 mg/d 14 days later. The control group was treated with oral rosuvastatin of 10mg/d before and after PCI. The intervention lasted for 1 month after operation. The thrombolysis in myocardial infarction (TIMI) grading in each group was observed at 1 week after operation. Left ventricular remodeling parameters [high-sensitivity C-reactive protein (hs-CRP), matrix metalloproteinase-9 (MMP-9)], serum CK-MB and cTnT levels were determined before and after operation. The major adverse cardiac events and adverse drug reactions in both groups during treatment were statistically analyzed. Results:The proportion of TIMI grade 3 in the observation group at 1 week after operation was significantly higher than that in the control group (93.33% vs 80.00%) (P<0.05). The levels of hs-CRP and MMP-9 in both groups increased significantly at 1 week after operation but the levels at 1 month after operation were significantly lower than those at 1 week after operation (P<0.05). The levels of serum CK-MB and cTnT in both groups decreased significantly at 1 week after operation, and the levels at 1 month after operation were significantly lower than those at 1 week after operation (P<0.05). The levels of hs-CRP, MMP-9, CK-MB and cTnT were significantly lower in the observation groupthan in the control group at 1 week and 1 month after operation (P<0.05). The incidence of severe arrhythmia in the observation group was significantly lower than that in the control group (P<0.05), but there was no significant difference in adverse drug reactions between the two groups (P>0.05). Conclusion:Compared with conventional dose, high-dose rosuvastatin can better improve myocardial reperfusion in patients with AMI after PCI, inhibit left ventricular remodeling, relieve myocardial injury, and reduce the incidence of severe arrhythmia, without increasing adverse drug reactions.
栗印军, 邢宇, 邢芸芸, 李赛, 王阳. 瑞舒伐他汀预处理对AMI术后心肌再灌注左心室重构及心肌损伤的影响[J]. 河北医学, 2019, 25(11): 1832-1836.
LI Yinjun, XING Yu, XING Yunyun, et al. Effect of Preconditioning with Rosuvastatin on Myocardial Reperfusion Left Ventricular Remodeling and Myocardial Injury after PCI for Acute Myocardial Infarction. HeBei Med, 2019, 25(11): 1832-1836.
[1] Yakar Tuluce S,Tuluce K,il Z,et al.Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function[J].Anatol Cardiol,2015,16(5):344~348. [2] 卓碧,韦庆新,韦盛锴,等.不同剂量瑞舒伐他汀对急性心肌梗死患者经皮冠状动脉介入治疗术后血清炎症因子及心功能相关指标的影响[J].山西医药杂志,2017,46(13):1551~1553. [3] 谢亚芹,赵娟,康大伟,等.不同剂量瑞舒伐他汀对急性心肌梗死大鼠心肌纤维化的影响及机制[J].广东医学,2018,39(2):195~198. [4] 解蓓.不同剂量瑞舒伐他汀对急性ST段抬高型心肌梗死患者经皮冠状动脉介入术后心肌再灌注的影响研究[J].实用心脑肺血管病杂志,2017,25(7):23~28. [5] 张兰芳,齐晓勇,贾新未,等.不同剂量瑞舒伐他汀对急性心肌梗死经皮冠状动脉介入治疗患者心肌再灌注及心功能的影响[J].中国临床药理学杂志,2015,31(13):1223~1226. [6] 李兆欣,刘江月,李静静,等.不同剂量瑞舒伐他汀治疗对急性心肌梗死患者心肌纤维化及心室重构的影响[J].中国循证心血管医学杂志,2016,8(1):46~50.
2019, Vol. 25 
冀公网安备13080202000677号